Syntans Picks Karur, Karnataka Bank Stakes

Image
BUSINESS STANDARD
Last Updated : Jan 28 2013 | 12:54 AM IST

The Chennai-based Indian Syntans Investments and associates, who hold major stakes in Aventis CropScience India and Bayer India, have picked up 2.5 per cent stake each in two private sector banks, Karur Vysya Bank and Karnataka Bank, through market purchases.

N Narayanan, chairman of Indian Syntans, said: "These two banks are doing well and our stake in them has recently touched 2.5 per cent. Since several leading private banks are takeover targets for a number of foreign banks, we are keen on making large scale investments in some banks."

In addition to these banks and other organisations, Indian Syntans has 4.5 per cent stake in Aventis India and recently it almost doubled its holding in Bayer India from 5.6 per cent to 11.4 per cent. However, Narayanan declined to comment on the total investment made by the group for acquiring the substantial holding.

"We are not keen on running these companies. Our main aim is to make returns on our investments. We are a 20-25 member professional company analysing chances of making investments. We have also exited some of the companies we invested earlier at the right time," he added.

Narayanan and associates have been making investments in the past 20-30 years in ethically-promoted companies. Before becoming an investor, Narayanan was a manufacturer of chemicals, and had a leather tanning business in Tamil Nadu.

According to Narayanan, his company does not want to become a predator, but will ask companies to maintain transparency in all their transactions. For instance, the company has said it will initiate legal action against Bayer India for undervaluation and selling its pharma sales and marketing division to Bayer Pharmaceuticals. Bayer Pharmaceuticals is a wholly owned subsidiary of Bayer AG.

It alleges the pharma marketing division was not properly valued and similar deals such as ICI and Abbot were valued at 1-1.5 times the revenue. The company feels that the value should be around Rs 60-70 crore, as against Rs 7 crore Bayer India received from Bayer Pharmaceuticals.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 20 2002 | 12:00 AM IST

Next Story